eprintid: 1555205 rev_number: 25 eprint_status: archive userid: 608 dir: disk0/01/55/52/05 datestamp: 2017-05-06 21:49:29 lastmod: 2021-09-20 22:27:27 status_changed: 2017-08-18 11:22:55 type: article metadata_visibility: show creators_name: Sola, E creators_name: Kerbert, AJC creators_name: Verspaget, HW creators_name: Moreira, R creators_name: Pose, E creators_name: Ruiz, P creators_name: Cela, R creators_name: Morales-Ruiz, M creators_name: Lopez, E creators_name: Graupera, I creators_name: Sole, C creators_name: Huelin, P creators_name: Amoros Navarro, A creators_name: Ariza, X creators_name: Jalan, R creators_name: Fabrellas, N creators_name: Benten, D creators_name: de Prada, G creators_name: Durand, F creators_name: Jimenez, W creators_name: van der Reijden, JJ creators_name: Fernandez, J creators_name: van Hoek, B creators_name: Coenraad, MJ creators_name: Gines, P title: Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis ispublished: pub divisions: UCL divisions: B02 divisions: C10 divisions: D17 divisions: G91 keywords: Science & Technology, Life Sciences & Biomedicine, Gastroenterology & Hepatology, Copeptin, Biomarker, Cirrhosis, Circulatory dysfunction, Prognosis, C-REACTIVE PROTEIN, ARGININE-VASOPRESSIN, RENAL-FUNCTION, HEPATORENAL-SYNDROME, VASOACTIVE SYSTEMS, HEART-FAILURE, HYPONATREMIA, MORTALITY, PRECURSOR, PEPTIDE note: © 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. abstract: BACKGROUND & AIMS: Research on vasopressin (AVP) in cirrhosis and its role in the assessment of prognosis has been hindered by the difficulty of measuring AVP levels accurately. Copeptin, a 39-aminoacid glycopeptide, is released from the neurohypophysis together with AVP. Copeptin could have a role as biomarker of prognosis in cirrhosis as it may reflect circulatory dysfunction. The aim of this study is to investigate the role of copeptin as biomarker of disease progression and prognosis in cirrhosis. METHODS: This prospective study is divided in 2 study protocols including 321 consecutive patients. Plasma copeptin levels were measured in all patients at study inclusion. Protocol 1: to investigate the relationship of copeptin with kidney and circulatory function (56 patients). Protocol 2: to investigate the relationship between copeptin and prognosis, as assessed by the development of complications of cirrhosis or mortality at 3 months (265 patients admitted to hospital for complications of cirrhosis). RESULTS: Patients with decompensated cirrhosis showed significantly higher plasma copeptin levels compared to those of patients with compensated cirrhosis. Copeptin levels had a significant positive correlation with model for end-satge liver disease (MELD) score, AVP, endogenous vasoconstrictor systems, and kidney function parameters. Patients developing complications of cirrhosis or mortality had significantly higher plasma copeptin levels compared to those of the remaining patients. Plasma copeptin levels were an independent predictive factor of both the development of complications and mortality at 3 months. This was confirmed in a validation series of 120 patients. CONCLUSIONS: Copeptin is a novel biomarker of disease progression and prognosis in cirrhosis. LAY SUMMARY: Copeptin is a fragment of the vasopressin precursor, a hormone that is known to be increased in patients with cirrhosis and that plays a role in the development of complications of the disease. Vasopressin is difficult to measure, but copeptin is a more stable molecule and is easier to measure in blood. Solà and Kerbert and colleagues have shown in a series of 361 patients that copeptin is markedly increased in patients with cirrhosis who develop complications during the following 3 months, compared to those patients who do not develop complications. Moreover, copeptin correlates with prognosis. date: 2016-11 date_type: published publisher: ELSEVIER SCIENCE BV official_url: http://doi.org/10.1016/j.jhep.2016.07.003 oa_status: green full_text_type: other language: eng primo: open primo_central: open_green article_type_text: Article verified: verified_manual elements_id: 1144751 doi: 10.1016/j.jhep.2016.07.003 lyricists_name: Jalan, Rajiv lyricists_id: RJALA78 actors_name: Jalan, Rajiv actors_name: Laslett, David actors_id: RJALA78 actors_id: DLASL34 actors_role: owner actors_role: impersonator full_text_status: public publication: Journal of Hepatology volume: 65 number: 5 pagerange: 914-920 pages: 7 issn: 1600-0641 citation: Sola, E; Kerbert, AJC; Verspaget, HW; Moreira, R; Pose, E; Ruiz, P; Cela, R; ... Gines, P; + view all <#> Sola, E; Kerbert, AJC; Verspaget, HW; Moreira, R; Pose, E; Ruiz, P; Cela, R; Morales-Ruiz, M; Lopez, E; Graupera, I; Sole, C; Huelin, P; Amoros Navarro, A; Ariza, X; Jalan, R; Fabrellas, N; Benten, D; de Prada, G; Durand, F; Jimenez, W; van der Reijden, JJ; Fernandez, J; van Hoek, B; Coenraad, MJ; Gines, P; - view fewer <#> (2016) Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis. Journal of Hepatology , 65 (5) pp. 914-920. 10.1016/j.jhep.2016.07.003 <https://doi.org/10.1016/j.jhep.2016.07.003>. Green open access document_url: https://discovery.ucl.ac.uk/id/eprint/1555205/1/Jalan_PLASMA%20COPEPTIN%20AS_A%20BIOMARKER%20OF%20DISEASE%20PROGRESSION%20AND%20PROGNOSIS%20IN%20CIRRHOSIS%20YL%2017Aug2017.pdf